Faulty signalling pathway linked to congenital heart condition

October 17, 2019

SINGAPORE, 17 October 2019 - A congenital heart condition known as left ventricular non-compaction (LVNC) - which occurs when muscly projections in the embryonic heart fail to transform into compact heart muscle - could be caused by signalling defects, according to new preclinical research led by Duke-NUS Medical School in Singapore. The finding, published in the journal JCI Insight, could pave the way towards potential diagnosis and therapies.

During normal embryonic heart development, muscle cells migrate and proliferate, forming finger-like protrusions inside the cardiac chamber. The projections, called trabeculae, help with heart nutrition and oxygenation until blood vessels form. They eventually dissolve, leading to the formation of a compact, smooth and solid heart wall. In some embryos, however, the trabeculae fail to dissolve and form solid heart wall, leading to LVNC, in which the trabeculae project into a thinned lower left heart chamber.

"LVNC is one of the most common disorders in cardiac chamber maturation. People born with this condition often do not experience any symptoms, but can be at higher risk of heart failure, irregular heart rhythms, or sudden cardiac arrest," said Assistant Professor Manvendra Singh, from Duke-NUS' Cardiovascular and Metabolic Disorders (CVMD) Programme, the senior and corresponding author of the study.

Globally, scientists' understanding of the molecular and genetic changes that lead to LVNC is limited. Asst Prof Singh and his colleagues in Singapore, Japan, and the USA wanted to test if a particular protein, Sema3E, is linked to the defects seen in LVNC. Sema3E is known to connect with a cell receptor, called PlexinD1, which is involved in embryonic heart development. However, Sema3E's existence in the heart had not yet been determined.

The team first turned off Plxnd1, the gene that codes for the PlexinD1 receptor, in a preclinical model of embryo hearts. This led to excessive formation of trabeculae that fail to become compacted, which typically happens in healthy heart walls.

Molecular analyses showed that turning off Plxnd1 led to increased activity from other genes initiated by a 'Notch signalling pathway'. Inhibiting this particular pathway partially prevented the hearts from developing malformations. The team also confirmed that many different types of cells in the developing hearts expressed Sema3E. Turning off the gene that codes for Sema3E significantly reduced heart wall thickness.

"Our study helped us to better understand the role of Semaphorin-Plexin signalling in this particular congenital cardiac condition," said Ms Reddemma Sandireddy, the study's lead author, who is a Research Assistant in the CVMD Programme. "The results indicate that Sema3E connects with its PlexinD1 receptor to turn off the Notch signalling pathway, thus suggesting its role in the formation and maturation of the lower heart chambers."

Professor Patrick Casey, Senior Vice Dean for Research at Duke-NUS Medical School, commented, "Currently, every third death in Singapore is due to cardiovascular diseases. Cardiomyopathy (heart muscle disease) is one of the most serious of the cardiovascular diseases, and this research expands our knowledge of one particular form of cardiomyopathy and may provide potential new targets to treat the condition."

The researchers say further studies could reveal more information about the processes that regulate heart development and lead to therapies for this and other congenital heart conditions.

Duke-NUS Medical School

Related Cardiovascular Diseases Articles from Brightsurf:

Graz researchers identify biomarker for cardiovascular diseases
The role of the enzyme dipeptidyl peptidase 3 in the blood pressure-regulating renin-angiotensin system was investigated in the inter-university cooperation project BioTechMed-Graz.

Glomerular diseases linked to higher risk of cardiovascular conditions
Adults with glomerular diseases have a 2.5-times higher risk of developing cardiovascular disease than individuals in the general population.

New insight into neovessel formation shows promise in future treatment of cardiovascular diseases
A new study by researchers at the University of Eastern Finland provides novel insight into the previously unknown effects of factors regulating blood vessel formation.

Research reveals cilia's role in cardiovascular functions and genetic diseases
Research from Chapman University discover ciliary extracellular-like vesicles (cELVs). Released by fluid-shear, cELVs act as nano-compartments within a cilium.

Stretching your legs may help prevent diseases such as heart diseases and diabetes
New research published today in The Journal of Physiology shows that 12 weeks of easy-to-administer passive stretching helps improve blood flow by making it easier for your arteries to dilate and decreasing their stiffness.

Framework on how to safely resume essential cardiovascular diagnostic and treatment care during the COVID-19 pandemic, from the AHA and 14 North American cardiovascular societies
The American Heart Association, together with 14 cardiovascular societies in North America, today issued joint guidance, 'Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership,' to outline a systematic, phased approach to safely reintroducing cardiovascular procedures for diagnosis and treatment during the COVID-19 pandemic.

Cardiovascular impairment in COVID-19
Anti-inflammatory therapies should be used to treat COVID-19 patients that are at risk of, or have developed, cardiovascular problems, recommend leading cardiologists from Beijing, China, who have detailed the different ways that COVID-19 could trigger serious inflammatory-related cardiovascular issues in patients.

A talk with your GP may prevent cardiovascular disease
Having a general practitioner (GP) who is trained in motivational interviewing may reduce your risk of getting cardiovascular disease.

Serum irisin: Pathogenesis and clinical research in cardiovascular diseases
In a new publication from Cardiovascular Innovations and Applications; Lutfu Askin, Kader Eliz Uzel, Okan Tanriverdi and Serdar Turkmen from the Department of Cardiology, Adiyaman Education and Research Hospital, Adiyaman, Turkey consider serum irisin pathogenesis and clinical research in cardiovascular diseases.

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications.

Read More: Cardiovascular Diseases News and Cardiovascular Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.